Historically, platinum-based doublet chemotherapy has been the standard first-line treatment for patients with advanced-stage NSCLC, particularly those without targetable epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genetic alterations (5–7). This evidence concerns the gene EGFR and non-small cell lung carcinoma.